Skincare Product Recalled for Temperature Storage Deviation
Family Dollar Stores is recalling AMBI Skincare Even & Clear Exfoliating Wash because the product was stored outside labeled temperature requirements during manufacturing. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II precautionary recall based on manufacturing storage deviations. The source explicitly states no illnesses or injuries reported, and the hazard is a theoretical product stability concern rather than a confirmed safety threat.
Plain-English summary
Family Dollar Stores is recalling AMBI Skincare Even & Clear Exfoliating Wash Salicylic Acid Acne Treatment (5 oz., SKU 2097153) distributed nationwide.
The recall was initiated due to a current Good Manufacturing Practice (cGMP) deviation: the product was stored at temperatures outside of the manufacturer's labeled temperature specifications during production. This storage condition may compromise product integrity and stability.
The product was distributed nationwide. Consumers who have purchased this product should stop use and may contact Family Dollar Stores or the FDA for additional information.
No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- AMBI Skincare Even & Clear Exfoliating Wash Salicylic Acid Acne Treatment With Oat and Sea Whip, Net Wt. 5 OZ. (141 g)
- Manufacturer
- Family Dollar Stores, Llc.
- Category
- Drug — Topical Skincare
- Hazard
- temperature-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- SKUs 2097153
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27